Core Viewpoint - The U.S. Food and Drug Administration has declined to approve Aquestive Therapeutics' oral drug for severe allergic reactions, indicating a setback for the company in its product development efforts [1] Company Summary - Aquestive Therapeutics has faced a significant regulatory hurdle as the FDA did not approve its oral drug intended for treating severe allergic reactions, which may impact the company's future revenue and market position [1]